Celcuity Inc. (CELC)
NASDAQ: CELCHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CELC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.61B
- EPS (TTM)
- -$4.72
- Dividend yield
- None
- 52-week range
- 53.20 – 151.02
- Day range
- 53.20 – 57.00
- Volume / Avg
- 636.53K / 1.25M
- Beta
- —
- Shares outstanding
- 48.93M
52-week range
CELC stock today
Shares of Celcuity (CELC) finished lower on Nov 20 at $53.35, a drop of 5.26% or $2.96 per share, versus the S&P 500's 3.70% decline. Shares are 64.7% below their 52-week high of $151.02, set on May 4, 2026 and 0.3% above the 52-week low of $53.20, near the bottom of the past year's range. CELC is down 46.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.3%.
Celcuity has posted a net loss over the last twelve months (EPS of -$4.72), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Celcuity
Company profileCelcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Brian F. Sullivan
- Headquarters
- Minneapolis, MN
- Employees
- 155
- IPO year
- 2017
- Website
- celcuity.com
Financial highlights
Full financialsCelcuity reported a net loss of $177.0 million, compared with a loss of $111.8 million a year earlier. Diluted earnings per share came in at -$3.79.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-177.04M | $-111.78M | $-63.78M | $-40.37M | $-29.61M |
| EPS (diluted) | $-3.79 | $-2.83 | $-2.69 | $-2.64 | $-2.21 |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$150.85+182.76%
- Strong buy 3
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-1.33 vs $-1.47
- Surprise
- +9.52%
CELC news
All CELC news- Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast CancerGlobeNewswire
- Celcuity Inc. Reports Third Quarter 2026 Financial Results and Commercial Launch of REVTORPYKNasdaq
- Celcuity Non-GAAP EPS of -$1.21 beats by $0.32Seeking Alpha
- Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- Celcuity To Participate in Upcoming Investor ConferencesGlobeNewswire
- Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference CallGlobeNewswire
- Celcuity says Revtorpyk boosts progression-free survival in breast cancerSeeking Alpha
- Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026GlobeNewswire
Celcuity peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VCYTVeracyte Inc. | 25.13 | +0.36% | $2.03B | vs CELC |
| ACHCAcadia Healthcare Company Inc. | 34.60 | +0.38% | $3.22B | vs CELC |
| CLOVClover Health Investments Corp. Class A | 3.73 | -1.06% | $2.00B | vs CELC |
| FTREFortrea Holdings Inc. | 18.55 | -7.94% | $1.79B | vs CELC |
| PSNLPersonalis Inc. | 14.27 | -3.06% | $1.55B | vs CELC |
| CDNACareDx Inc. | 70.00 | -2.67% | $3.68B | vs CELC |
| TRUPTrupanion Inc. | 35.56 | -0.86% | $1.54B | vs CELC |
| LMRILumexa Imaging Holdings Inc. | 14.26 | +1.42% | $1.37B | vs CELC |
Indexes, lists and sector
Celcuity stock FAQ
What is Celcuity's stock price today?
CELC last traded at $53.35 as of Nov 20, 4:00 PM EST, down 5.26% on the day. Prices are delayed at least 15 minutes.
Who is Celcuity's CEO?
Mr. Brian F. Sullivan is the chief executive officer of Celcuity Inc., which has about 155 employees.
What is the CELC 52-week high?
The 52-week high for CELC is $151.02 and the 52-week low is $53.20. The stock is currently 64.7% below its high.